Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tacrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 16/20 | 0.97 |
| ▸ | BCHE known ✓ | P06276 | 14/20 | 0.97 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.93 |
| ▸ | GRIN2A | Q12879 | 8/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.93 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.93 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.93 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.93 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.93 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.93 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tacrine SCHEMBL5580054 | 1.00 | THRB (1.00) | THRBCYP1A2CYP2D6ACHEBCHE | |
| Tacrine SCHEMBL2330283 | 0.98 | ACHE (1.00) | THRBCYP1A2CYP2D6ACHEBCHE | |
| Tacrine SCHEMBL2330285 | 0.98 | ACHE (1.00) | THRBCYP1A2CYP2D6ACHEBCHE | |
| Tacrine SCHEMBL9407893 | 0.98 | CYP1A2 (0.97) | THRBCYP1A2CYP2D6ACHEBCHE | |
| Tacrine SCHEMBL3270 | 0.98 | ACHE (1.00) | THRBCYP1A2CYP2D6ACHEBCHE | |
| Tacrine SCHEMBL490750 | 0.98 | ACHE (1.00) | THRBCYP1A2CYP2D6ACHEBCHE | |
| Tacrine SCHEMBL7638777 | 0.98 | ACHE (1.00) | THRBCYP1A2CYP2D6ACHEBCHE | |
| Tacrine SCHEMBL1044163 | 0.98 | ACHE (1.00) | THRBCYP1A2CYP2D6ACHEBCHE | |
| Tacrine SCHEMBL28574261 | 0.97 | CYP1A2 (0.94) | THRBCYP1A2CYP2D6ACHEBCHE | |
| Tacrine SCHEMBL27895837 | 0.97 | CYP1A2 (0.94) | THRBCYP1A2CYP2D6ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | claimed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | claimed |
| EP-4429648-B1 | NOVEL SYNERGISTIC COMBINATIONS BASED ON FLUOROETHYLNOREMMANTINE (FENM) AND AN ACETYLCHOLINESTERASE INHIBITOR FOR USE IN THE TREATMENT OF NEURODEGEATIVE DISEASES | REST THERAPEUTICS (FR) | 2026-05-13 | — | — | EP | disclosed |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | Didenko, Kirill (US) | 2025-07-03 | — | — | US | disclosed |
| US-12310944-B2 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2025-05-27 | — | — | US | disclosed |
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250000818-A1 | NEW SYNERGISTIC COMBINATIONS BASED ON FENM AND AN ACETYLCHOLINESTERASE INHIBITOR | REST THERAPEUTICS (FR) | 2025-01-02 | — | — | US | disclosed |
| EP-4429648-A1 | NEW SYNERGISTIC COMBINATIONS BASED ON FENM AND AN ACETYLCHOLINESTERASE INHIBITOR | REST THERAPEUTICS (FR) | 2024-09-18 | — | — | EP | disclosed |
| CN-113603684-B | 1,2, 4-oxadiazole Nrf2 activator-tac Lin Pinge product and preparation method and application thereof | 中国药科大学 | 2023-12-19 | — | — | CN | disclosed |
| WO-2023187599-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | DIDENKO KIRILL (MX) | 2023-10-05 | — | — | WO | disclosed |
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-1996000065-A1 | TACRINE PHARMACEUTICAL COMPOSITIONS | ALZA CORPORATION (US) | 1996-01-04 | — | — | WO | disclosed |
| US-5466696-A | Mixtures for treatment of alzheimer's disease | WARNER LAMBERT COMPANY (US) | 1995-11-14 | — | — | US | disclosed |
| EP-0659082-A1 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER-LAMBERT COMPANY (US) | 1995-06-28 | — | — | EP | disclosed |
| US-5422350-A | Alzheimer's disease | WARNER-LAMBERT COMPANY (US) | 1995-06-06 | — | — | US | disclosed |
| WO-1995003052-A1 | CONTROLLED RELEASE TACRINE DRUG DELIVERY SYSTEMS AND METHODS FOR PREPARING SAME | WARNER-LAMBERT COMPANY (US) | 1995-02-02 | — | — | WO | disclosed |
| WO-1994005296-A2 | USE OF CYTOCHROME P450 INHIBITORS FOR INHIBITING THE METABOLISM OF NITROGEN SUBSTITUTED ACRIDINE | WARNER-LAMBERT COMPANY (US) | 1994-03-17 | — | — | WO | disclosed |
| WO-1992014443-A1 | MICROSPHERE-IN-OIL EMULSION | WARNER-LAMBERT COMPANY (US) | 1992-09-03 | — | — | WO | disclosed |
| EP-0449172-A1 | A method of reducing a carbonyl containing acridine | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-10-02 | — | — | EP | disclosed |
| US-5053513-A | Catalytic hydrogenation using noble metal catalyst, lithium hydroxide, solvent | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | BCHE, ACHE, BACE1 | ACHE 2/4885BCHE 1/4885THRB 4252/4885 |
| US-20250213601-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES | ACE2, FURIN, SARS1 | ACHE 1160/4885BCHE 1047/4885THRB 3882/4885 |
| US-12310944-B2 | Selective butyrylcholinesterase inhibitor or pharmaceutically acceptable salt thereof, preparation method and use thereof | BCHE, ACHE, BACE1 | ACHE 2/4885BCHE 1/4885THRB 4241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.